Key Highlights

  • The stock climbed USD 0.5964, or 83.54%, to USD 1.3103 in pre-market trading on November 4, 2026.
  • Cash and cash equivalents were USD 5.1 million at June 30, 2026, against USD 15.0 million at March 31, 2026.
  • The first-half net loss was USD 32.8 million for 2026, compared with USD 19.2 million a year earlier.
  • A 1-for-20 Reverse Stock Split took effect on July 2, 2026, with split-adjusted trading starting July 6, 2026.
  • An August 2026 public offering brought in about USD 4.8 million in net proceeds.

What Moved Curis Before the Open (up USD 0.5964, 83.54%)

Curis (NASDAQ:CRIS) gained 83.54%, or USD 0.5964, to USD 1.3103 in pre-market trading on November 4, 2026. That implies a Tuesday, November 3, 2026 close of about USD 0.7139 (calculated from the screen data).

No company press release, regulatory filing or clinical update dated November 2 to November 4, 2026 was identified as the trigger. The jump therefore looks like speculative momentum in a very small biotech stock, rather than a response to a disclosed event.

What Does the Latest Disclosure Show?

Curis is a clinical-stage biotechnology company whose lead candidate, emavusertib, is an oral inhibitor of IRAK4 and FLT3 being tested in blood cancers. According to its second-quarter 2026 report, cash and cash equivalents were USD 5.1 million at June 30, 2026, down from USD 15.0 million at March 31, 2026.

The net loss was USD 8.6 million for the quarter, unchanged from the same period of 2025, and USD 32.8 million for the six months, up from USD 19.2 million. First-half operating expenses fell to USD 21.5 million from USD 23.5 million. Research and Development spending dropped 18%, while general and administrative costs rose 10% on costs tied to the January 2026 private Placement and higher legal fees.

Pipeline, Split and Financing Details

Emavusertib is being tested in two Phase 2 style studies: TakeAim Lymphoma, with ibrutinib in primary central nervous system lymphoma, and TakeAim CLL, with zanubrutinib in chronic lymphocytic leukemia. The company said in June 2026 that eleven sites were open for the CLL study and that data from the first patients were expected in December 2026.

Shareholders approved a reverse split in June 2026, and the board set the ratio at 1-for-20. It became effective at 5:00 p.m. Eastern time on July 2, 2026, and the stock kept the CRIS ticker. The company said the step was meant to restore compliance with the Nasdaq minimum bid price rule.

In January 2026 the company arranged a private placement of up to USD 80.8 million in gross proceeds, including about USD 20.2 million upfront plus warrants. In August 2026 it completed a public offering with about USD 4.8 million in net proceeds.

Balance Sheet, Dilution and Risks

Management said cash and the August proceeds should fund operations into the fourth quarter of 2026 and that substantial additional Capital is needed. The company also said it does not expect to be profitable in the foreseeable future, and it plans to raise funds through equity, collaborations or strategic transactions.

At a price near USD 1.31 the shares are a penny stock. That brings sharp volatility, thin Liquidity and a real risk of further dilution, particularly because runway is short and warrants remain outstanding.

What Should Readers Watch Next?

The third-quarter 2026 Business update should show cash at September 30, 2026 and any change to the runway guidance.

On the clinical side, the first TakeAim CLL patient data, expected in December 2026, are the nearest scientific marker.